Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Context: Antidrug antibodies (ADA) can potentially affect drug pharmacokinetics, safety, and efficacy.
Objective: This work aimed to evaluate treatment-emergent (TE) ADA in tirzepatide (TZP)-treated participants across 7 phase 3 trials and their potential effect on pharmacokinetics, efficacy, and safety.
Methods: ADA were assessed at baseline and throughout the study until end point, defined as week 40 (SURPASS-1, -2, and -5) or week 52 (SURPASS-3, -4, Japan-Mono, and Japan-Combo). Samples for ADA characterization were collected at SURPASS trial sites. Participants included ADA-evaluable TZP-treated patients with type 2 diabetes (N = 5025). Interventions included TZP 5, 10, or 15 mg. ADA were detected and characterized for their ability to cross-react with native glucose-dependent insulinotropic polypeptide (nGIP) and glucagon-like peptide-1 (nGLP-1), neutralize tirzepatide activity on GIP and GLP-1 receptors, and neutralize nGIP and nGLP-1.
Results: TE ADA developed in 51.1% of tirzepatide-treated patients. Proportions were similar across dose groups. Maximum ADA titers ranged from 1:20 to 1: 81 920 among TE ADA+ patients. Neutralizing antibodies (NAb) against TZP activity on GIP and GLP-1 receptors were observed in 1.9% and 2.1% of patients, respectively. Less than 1.0% of patients had cross-reactive NAb against nGIP or nGLP-1. TE ADA status, ADA titer, and NAb status had no effect on the pharmacokinetics or efficacy of TZP. More TE ADA+ patients experienced hypersensitivity reactions or injection site reactions than TE ADA- patients. The majority of hypersensitivity and injection site reactions were nonserious and nonsevere, and most events occurred and/or resolved irrespective of TE ADA status or titer.
Conclusion: Immunogenicity did not affect TZP pharmacokinetics or efficacy. The majority of hypersensitivity or injection site reactions experienced by TE ADA+ patients were mild to moderate in severity.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10795913 | PMC |
| http://dx.doi.org/10.1210/clinem/dgad532 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Estimands for Early-Phase Dose Optimization Trials in Oncology.
Biom J
October 2025
Novella Clinical Full Service, IQVIA, Melbourne, Australia.
Phase I dose escalation trials in oncology generally aim to find the maximum tolerated dose. However, with the advent of molecular-targeted therapies and antibody drug conjugates, dose-limiting toxicities are less frequently observed, giving rise to the concept of optimal biological dose (OBD), which considers both efficacy and toxicity. The estimand framework presented in the addendum of the ICH E9(R1) guidelines strengthens the dialogue between different stakeholders by bringing in greater clarity in the clinical trial objectives and by providing alignment between the targeted estimand under consideration and the statistical analysis methods.
View Article and Find Full Text PDFTherapeutic Efficacy and Drug Metabolism of Griseorhodin A Induced by a Co-culture of Actinomycete Strain TMPU-20A002 and Mycobacterium smegmatis in Silkworm Infection Models.
Chem Pharm Bull (Tokyo)
September 2025
Division of Natural Product Chemistry, Faculty of Pharmaceutical Sciences, Tohoku Medical and Pharmaceutical University, 4-4-1 Komatsushima, Aoba-ku, Sendai 981-8558, Japan.
In screening for antibacterial agents from co-cultures of Mycobacterium smegmatis and microbial resources, such as actinomycetes and fungi, the known hydroxyquinone antibiotic griseorhodin A (1) was isolated from a co-culture of actinomycete strain TMPU-20A002 and M. smegmatis. Compound 1 exhibited antibacterial activity against methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant Enterococcus faecalis (VRE), with minimum inhibitory concentrations of 0.
View Article and Find Full Text PDFPopulation pharmacokinetics of intravenous ampicillin in awake and anesthetised dogs.
Vet J
September 2025
Inserm U955-IMRB, Equipe 03 "Pharmacologie et Technologies pour les Maladies Cardiovasculaires (PROTECT)", Ecole Nationale Vétérinaire d'Alfort (EnVA), Université Paris Est Créteil, F-94700 Maisons-Alfort, France; Ecole Nationale Vétérinaire d'Alfort, Maisons-Alfort, France. Electronic address
The aim of this study is to describe a population pharmacokinetic model for intravenous ampicillin-sulbactam in awake and anaesthetized dogs in these two treatment scenarios and to compute PK/PD cut-offs (PK/PD). This was a prospective clinical trial in 20 client-owned dogs, either treated by ampicillin after post-surgical infection, or in the context of surgical antimicrobial prophylaxis. All animals received 20mg/kg of ampicillin by slow iv route.
View Article and Find Full Text PDFDST-3, a novel cryptotanshinone derivate, attenuates glutamate excitotoxicity after ischemic stroke via CREB-Homer1 axis activation.
Phytomedicine
September 2025
National and Local United Engineering Lab of Druggability and New Drugs Evaluation, Guangdong Provincial Key Laboratory of New Drug Design and Evaluation, Guangdong Province Engineering Laboratory for Druggability and New Drug Evaluation, School of Pharmaceutical Sciences, Sun Yat-sen University, Gu
Background: Ischemic stroke remains a leading cause of death and disability worldwide. While cryptotanshinone (CTS) shows therapeutic promise, its clinical application is hindered by poor pharmacokinetic properties. This study investigated DST-3, a novel derivative of CTS for enhanced neuroprotective effect against ischemic stroke with improved drug-like properties.
View Article and Find Full Text PDFPharmacokinetics of carprofen in Siamese crocodiles (Crocodylus siamensis).
Res Vet Sci
September 2025
Department of Pharmacology, Faculty of Veterinary Medicine, Kasetsart University, Bangkok, Thailand. Electronic address:
Carprofen (CAR) is an NSAID commonly used in veterinary medicine that preferentially inhibits cyclooxygenase-2 (COX-2), thereby mitigating inflammation and pain while minimizing adverse effects linked to cyclooxygenase-1 (COX-1) inhibition. This study characterizes the pharmacokinetics of CAR in Siamese crocodiles (Crocodylus siamensis) and was conducted at an ambient temperature range of 27-30 °C following single intravenous (IV) or intramuscular (IM) administration at 2 mg/kg, and IM administration at 4 mg/kg. Plasma concentrations were determined using a validated high-performance liquid chromatography method with ultraviolet detection (HPLC-UV).
View Article and Find Full Text PDF